September 5, 2016 – Örebro University Hospital in Sweden will start using RayPilot® for real-time tracking in a clinical trial on prostate cancer patients. The study is named "Assessment of acute side effects effect of 14Gy HDR brachytherapy in combination with hypo-fractionated external beam radiotherapy (3 Gy x 14) in the treatment of localised prostate cancer with a small external beam margin of 3 mm and real time positioning – a randomised study comparing two different overall treatment times.".
• The prostate gland has both interfractional and intrafractional motion. Now we will have full control of this with two different techniques, brachytherapy and real-time positioning with RayPilot® says MD, PhD. Bengt Johansson, senior oncologist at Örebro University Hospital.
In the study, patients will receive a combination of brachytherapy and hypofractionated external beam radiotherapy where RayPilot® will be used for target tracking in the external treatment and the radiation will be interrupted when the target moves more than 3 mm.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
• It's great that we will start working with Örebro University Hospital, which has a long tradition of both high precision treatment techniques and hypofractionation of prostate cancer. The study aims to improve the efficiency of treatment and reduce the risk of side effects, RayPilot® will be used as the tool to ensure a high precision. The goal is also to expand the use of RayPilot into prostate SBRT treatment and to additionally examine the possibility of using the system to increase the precision of other cancers. The clinic has already visited a RayPilot® reference site and discussions on a multinational cooperation regarding the treatment of gynecological cancer has begun, says Micropos CEO, Tomas Gustafsson.
The installation is scheduled for autumn 2016 and Örebro University Hospital will be able to follow the movements of the target in real time (30 times per second) without adding any additional potentially harmful X-rays.
Already an inquiry has been received from a foreign clinic to make a study visit.
It is possible that additional clinics will join the study.
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic positioning and real time tracking system for a fast and objective set-up and for continuous positioning during radiotherapy. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. The next generation of the RayPilot® transmitter with an unique combination of positioning, in-situ dosimetry and automatic patient identification is work in progress. RayPilot® is CE certified for prostate and surface use. Follow us on Facebook, www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS.
Back to HCB News
